ROCKVILLE, Md., April 9, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) announced today that Chief Executive Officer Martin Rosendale discussed the company and his leadership style in an interview on The Leaders Spot with Rebecca Blacksmith.
Mr. Rosendale was a featured guest on The Leaders Spot with Rebecca Blacksmith, which airs on Washington Business Talk Radio. His interview aired during the program on April 8, 2009 from 11am-noon on www.TheLeadersSpot.com and WDMV AM 700 and is available on-demand 24/7 as a podcast at http://theleadersspot.com/archives/1150. A link to the podcast is also available on the Company's website at www.Cytomedix.com
The Leaders Spot with Rebecca Blacksmith features top business leaders discussing their respective leadership styles, philosophies, challenges, successes and industry trends.
ABOUT THE LEADERS SPOT WITH REBECCA BLACKSMITH
The Leaders Spot with Rebecca Blacksmith is an interview show hosted by a Leader, about top leaders, for all leaders. Blacksmith has conducted over 2000 elite interviews and is currently working on her third Ivy League graduate degree. Rebecca's fun and intelligent conversations with these DC area CEOs and business leaders focus on navigating methods for serious leadership. For information, visit The Leaders Spot with Rebecca Blacksmith at www.TheLeadersSpot.com.
ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, including the AutoloGel(tm) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(tm) System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. Additional information regarding Cytomedix is available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this communication, and the referenced interview, not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, viability and effectiveness of the Company's sales approach and overall marketing strategies, and Cytomedix's ability to execute on its strategy to market the AutoloGelTM System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.